Glucagon-like peptide 1 receptor agonists (GLP-1Ra) are a popular class of medication that has been shown to reduce cancer risk, but their effects on patients with neuroendocrine neoplasms (NENs) have not yet been studied. This evidence concerns the gene GLP1R and neuroendocrine neoplasm.